Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)

NCT ID: NCT01292031

Last Updated: 2016-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

232 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To demonstrate that colistin iv. is not inferior to meropenem in empiric treatment of VAP regarding the final point of primary efficacy: mortality in the 28 subsequent days and clinical healing in patients clinically evaluated.
2. To compare the safety of treatment with colistin vs meropenem in VAP.
3. To compare microbiological efficacy of treatment with colistin vs meropenem in VAP

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study drugs: Patients will be randomized a 1:1 rate and open label fashion to two interventions: group 1: colistin loading dose followed by colistin infusion iv/8h or group 2: meropenem 2 g/iv/ 8 h. The overall treatment time will be a minimum of 8 days.

Follow-up visits will be performed at baseline, 72 h, 8 days, the end of treatment, and 28 days from recruitment ICU discharge, hospital discharge or death.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventilator-associated Bacterial Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colistin

Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion

Group Type EXPERIMENTAL

Colistin

Intervention Type DRUG

Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion

Meropenem

Meropenem 2 g/iv/ 8 h. 30 minutes infusion

Group Type ACTIVE_COMPARATOR

Meropenem

Intervention Type DRUG

Meropenem 2 g/iv/ 8 h. 30 minutes infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colistin

Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion

Intervention Type DRUG

Meropenem

Meropenem 2 g/iv/ 8 h. 30 minutes infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age ≥ 18 years with clinical and radiological criteria of VAP. The women of childbearing age (not surgically sterilized and in the period between menarche and 1 year after the menopause) must have a negative test of pregnancy in urine at the time of recruitment.

The patient or his/her legal representative must sign a document of informed consent approved by the Ethics Review Committee.

Exclusion Criteria

Hypersensitivity to the two antimicrobials of the study (colistin/meropenem). Renal insufficiency in substitute treatment. Corporal weight \<40 kg or \>150 kg. Patients previously included in another clinical trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Commission

OTHER

Sponsor Role collaborator

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

José Miguel Cisneros-Herreros, PhD

Role: STUDY_CHAIR

Andaluz Health Service

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Alexandroupolis, Medical School University of Thrace

Alexandroupoli, , Greece

Site Status

Evagelismos Hospital, Medical School University of Athens

Athens, , Greece

Site Status

General Hospital of Larissa, Thessalia University

Athens, , Greece

Site Status

Sotiria Hospital, Medical School University of Athens

Athens, , Greece

Site Status

University Hospital Ag. Anargiri, Nurshing School University of Athens

Athens, , Greece

Site Status

University Hospital ATTIKON, Medical School University of Athens

Athens, , Greece

Site Status

University Hospital of Larissa, Medical School University of Athens

Athens, , Greece

Site Status

University Hospital of Heraklion, Medical School University of Crete

Crete, , Greece

Site Status

University Hospital of Ioannina, Medical School, University of Ipirus

Ioannina, , Greece

Site Status

Papanikolaou Hospital,

Thessaloniki, , Greece

Site Status

Azienda OspedalieraSant'Andrea

Roma, Rome, Italy

Site Status

AO Ospedale Niguarda Ca Granda Milano

Milan, , Italy

Site Status

University of Napoli Federico II

Napoli, , Italy

Site Status

AOU Cisanello- Pisa

Pisa, , Italy

Site Status

Policlinico Universitario A. Gemelli

Roma, , Italy

Site Status

S.Giovanni Battista Molinette Hospital Turin

Turin, , Italy

Site Status

University Hospital Reina Sofía

Córdoba, Córdoba, Spain

Site Status

University Hospital Juan Ramón Jiménez

Huelva, Huelva, Spain

Site Status

Complexo Hospitalario A Coruña

A Coruña, , Spain

Site Status

Hospital Puerta del Mar Universidad de Cádiz

Cadiz, , Spain

Site Status

Hospital General Universitario Santa Lucía

Cartagena, , Spain

Site Status

Hospital General de Ciudad Real

Ciudad Real, , Spain

Site Status

Hospital de Jerez

Jerez de la Frontera, , Spain

Site Status

Hospital 12 de Octubre

Madrid, , Spain

Site Status

Hospital Clínico San Carlos

Madrid, , Spain

Site Status

Hospital Carlos Haya Universidad de Málaga

Málaga, , Spain

Site Status

Hospital Universitario Virgen de la Victoria

Málaga, , Spain

Site Status

Complexo Hospitalario de Orense

Ourense, , Spain

Site Status

Hospital Marqués de Valdecillas

Santander, , Spain

Site Status

Hospital Virgen del Rocío Sevilla

Seville, , Spain

Site Status

Hospital Mutua de Terrassa

Tarrasa, , Spain

Site Status

La Fe Universidad de Valencia

Valencia, , Spain

Site Status

Hospital Dr. Peset

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece Italy Spain

References

Explore related publications, articles, or registry entries linked to this study.

Cisneros JM, Rosso-Fernandez CM, Roca-Oporto C, De Pascale G, Jimenez-Jorge S, Fernandez-Hinojosa E, Matthaiou DK, Ramirez P, Diaz-Miguel RO, Estella A, Antonelli M, Dimopoulos G, Garnacho-Montero J; Magic Bullet Working Group WP1. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care. 2019 Nov 28;23(1):383. doi: 10.1186/s13054-019-2627-y.

Reference Type DERIVED
PMID: 31779711 (View on PubMed)

Rosso-Fernandez C, Garnacho-Montero J, Antonelli M, Dimopoulos G, Cisneros JM; MagicBullet study group. Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials. 2015 Mar 20;16:102. doi: 10.1186/s13063-015-0614-4.

Reference Type DERIVED
PMID: 25872790 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-023310-31

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.